• M Eugenia Dieterle, Denise Haslwanter, Robert H Bortz, Ariel S Wirchnianski, Gorka Lasso, Olivia Vergnolle, Shawn A Abbasi, J Maximilian Fels, Ethan Laudermilch, Catalina Florez, Amanda Mengotto, Duncan Ki... more mmel, Ryan J Malonis, George Georgiev, Jose Quiroz, Jason Barnhill, Liise-Anne Pirofski, Johanna P Daily, John M Dye, Jonathan R Lai, Andrew S Herbert, Kartik Chandran, and Rohit K Jangra. less
• Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
• Cell Host Microbe. 2020 Sep 9; 28 (3): 486-496.e6.

AbstractThere is an urgent need for vaccines and therapeutics to prevent and treat COVID-19. Rapid SARS-CoV-2 countermeasure development is contingent on the availability of robust, scalable, and readily deployable surrogate viral assays to screen antiviral humoral responses, define correlates of immune protection, and down-select candidate antivirals. Here, we generate a highly infectious recombinant vesicular stomatitis virus (VSV) bearing the SARS-CoV-2 spike glycoprotein S as its sole entry glycoprotein and show that this recombinant virus, rVSV-SARS-CoV-2 S, closely resembles SARS-CoV-2 in its entry-related properties. The neutralizing activities of a large panel of COVID-19 convalescent sera can be assessed in a high-throughput fluorescent reporter assay with rVSV-SARS-CoV-2 S, and neutralization of rVSV-SARS-CoV-2 S and authentic SARS-CoV-2 by spike-specific antibodies in these antisera is highly correlated. Our findings underscore the utility of rVSV-SARS-CoV-2 S for the development of spike-specific therapeutics and for mechanistic studies of viral entry and its inhibition.Copyright © 2020 Elsevier Inc. All rights reserved.

71 keywords...

hide…